BeiGene Ltd. (BGNE)
Stock Price Chart
Key Info
| Market Cap | 19.07B |
| Revenue (ttm) | 224.73M |
| Net Income (ttm) | -1.39B |
| Shares Out | 90.02M |
| EPS (ttm) | -20.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $211.80 |
| Previous Close | $215.38 |
| Change ($) | -3.58 |
| Change (%) | -1.66% |
| Day's Open | 213.16 |
| Day's Range | 210.52 - 214.32 |
| Day's Volume | 41,518 |
| 52-Week Range | 114.41 - 256.01 |
More Stats
| Market Cap | 19.07B |
| Enterprise Value | 16.28B |
| Earnings Date (est) | Nov 5, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 90.02M |
| Float | 44.66M |
| EPS (basic) | -1.58 |
| EPS (diluted) | -20.22 |
| FCF / Share | -15.93 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 2.74M |
| Short Ratio | 6.22 |
| Short % of Float | n/a |
| Beta | 1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 84.84 |
| PB Ratio | 7.87 |
| Revenue | 224.73M |
| Operating Income | -1.43B |
| Net Income | -1.39B |
| Free Cash Flow | -1.24B |
| Net Cash | 2.79B |
| Net Cash / Share | 31.01 |
| Gross Margin | -253.78% |
| Operating Margin | -637.63% |
| Profit Margin | -620.50% |
| FCF Margin | -550.69% |
| ROA | -29.59% |
| ROE | -67.89% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 428 | 198 | 238 | 1.07 | 8.82 | 13.04 | 11.15 |
| Revenue Growth | 116.03% | -16.85% | 22179.16% | -87.86% | -32.37% | 16.93% | - |
| Gross Profit | 357 | 170 | 233 | 1.07 | 8.82 | 13.04 | 11.15 |
| Operating Income | -960 | -706 | -98.46 | -117 | -56.75 | -15.76 | -5.57 |
| Net Income | -949 | -674 | -93.11 | -119 | -57.10 | -18.28 | -7.49 |
| Shares Outstanding | 781 | 721 | 543 | 404 | 111 | 99.86 | 91.48 |
| Earnings Per Share | -1.22 | -0.93 | -0.17 | -0.30 | -0.52 | -0.18 | -0.08 |
| Operating Cash Flow | -750 | -548 | 12.75 | -89.51 | -39.84 | -8.69 | 4.07 |
| Capital Expenditures | -89.61 | -70.28 | -58.73 | -23.50 | -5.31 | -0.65 | -0.25 |
| Free Cash Flow | -840 | -618 | -45.98 | -113 | -45.16 | -9.35 | 3.82 |
| Cash & Equivalents | 983 | 1,796 | 838 | 368 | 100 | 44.40 | 3.93 |
| Total Debt | 277 | 198 | 165 | 17.28 | 20.79 | 13.84 | 27.36 |
| Net Cash / Debt | 706 | 1,598 | 673 | 351 | 79.70 | 30.56 | -23.44 |
| Assets | 1,612 | 2,250 | 1,046 | 406 | 117 | 53.62 | 11.80 |
| Liabilities | 634 | 496 | 362 | 52.91 | 42.45 | 27.85 | 48.76 |
| Book Value | 962 | 1,739 | 670 | 353 | -102 | -53.04 | -40.49 |
Company Profile
Company Details
| Full Name | BeiGene Ltd. |
| Country | China |
| Employees | 4,200 |
| CEO | John V. Oyler |
Stock Information
| Ticker Symbol | BGNE |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: BGNE |
| IPO Date | February 3, 2016 |
Description
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.